Clinical trials
Alpha1-Antitrypsin Deficiency clinical trials
Below are recruiting alpha1-antitrypsin deficiency clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06512454Recruiting
Study on inherited alpha-1 antitrypsin deficiency and related liver problems
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
Gainesville, FloridaAges 18 years+ - NCT07555483RecruitingPhase 3
Weekly injection vs IV infusion for alpha-1 antitrypsin deficiency
This trial tests whether a new weekly injection form of alpha-1 antitrypsin replacement therapy (a protein your body lacks) works as well as the standard IV infusion you may currently receive. The goal is to offer a more convenient treatment option for people with alpha-1 antitrypsin deficiency (a genetic lung condition).
Birmingham, AlabamaAges 18–80 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Birmingham, AlabamaAges 18–75 - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Phoenix, ArizonaAges 18–75 - NCT06892236Enrolling by invitation
Creating gene-corrected stem cells for Alpha-1 Antitrypsin Deficiency
This trial uses your own cells to create stem cells (iPSCs) that can be genetically corrected to treat severe Alpha-1 Antitrypsin Deficiency. It is an early study exploring a potential cure.
Pavia, PaviaAges 18 years+
Hear when a new Alpha1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Alpha1-Antitrypsin Deficiency trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for alpha1-antitrypsin deficiency?
- Yes. Clin2 currently lists 5 recruiting alpha1-antitrypsin deficiency studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alpha1-antitrypsin deficiency trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alpha1-antitrypsin deficiency trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.